Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma.

Trial Profile

Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2012

At a glance

  • Drugs Dasatinib (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jan 2009 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top